[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"red-blood-cell-disorder\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:red-blood-cell-disorder":30},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,51],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100302225","phase-2-nonmyeloablative-stem-cell-transplant-in-children-with-sickle-cell-disease-and-a-major-abo-incompatible-matched-sibling-donor-100302225",false,"NCT03214354","Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor","A Phase II Pilot Study of Nonmyeloablative Conditioning Hematopoietic Stem Cell Transplantation in Children With Sickle Cell Disease Who Have a Matched Related Major ABO-Incompatible Donor (Sickle-AID)","Sickle-AID","Inclusion Criteria:\n\n* Patients must be ≥ 12 months and \\\u003C 19 years of age at the time of study enrollment.\n* Patients must have sickle cell disease as defined by hemoglobin electropheresis, as follows:\n\n  * homozygous Hb S disease (HbSS),\n  * sickle-Hb C disease (HbSC),\n  * sickle beta-plus-thalassemia (HbS\u002Fβ+), or\n  * sickle beta-null-thalassemia (HbS\u002Fβo)\n* Patients must meet standard eligibility criteria to undergo HSCT, including but not limited to one or more of the following:\n\n  * history of repeated (more than 1) bony (vaso-occlusive) crisis\n  * history of stroke\n  * elevated transcranial Doppler velocity not eligible for hydroxyurea, as per TWiTCH trial (ie. severe vasculopathy)\n  * history of acute chest crisis or splenic sequestration crisis\n  * history of priapism in males\n  * history of osteonecrosis\n  * pulmonary hypertension as documented by tricuspid regurgitation jet velocity (TRV) \\> 2.5 m\u002Fs on echocardiogram\n  * red cell allo-immunization (≥ 2 antibodies) during long term transfusion therapy\n* Sickle complications should be present despite the use of hydroxyurea, but this is not an absolute requirement, if the treating team considers the patient to be at high risk for further crisis episodes.\n\nExclusion Criteria:\n\n* Patients who are unable to comply with or follow the study protocol.\n* Patients with known hypersensitivity to sirolimus, its derivatives or to any of its components.","ALL","1 Year","19 Years",{"count":21,"type":22},12,"ESTIMATED","INTERVENTIONAL",[25],"PHASE2","The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a matched related major ABO-incompatible donor. The nonmyeloablative regimen will use alemtuzumab, total body irradiation (TBI) and sirolimus for immune suppression. This study will expand the access of HSCT for patients with SCD who are currently not eligible because of donor restrictions.",[28,29,30,31],"Sickle Cell Disease","Stem Cell Transplant Complications","Red Blood Cell Disorder","Pure Red Cell Aplasia",[33,34,35,36,37],"sickle cell disease","stem cell transplant","red blood cell engraftment","nonmyeloablative","pure red cell aplasia","RECRUITING","2026-04-27",{"date":41,"type":42},"2026-05-01","ACTUAL",{"date":44,"type":42},"2017-07-05",{"date":46,"type":22},"2028-07",{"name":48,"class":49},"University of Calgary","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":56,"eligibilityCriteria":57,"healthyVolunteers":58,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":59,"targetDuration":4,"studyType":61,"phases":4,"briefSummary":62,"conditions":63,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":64,"lastUpdatePostDateStruct":65,"startDateStruct":67,"completionDateStruct":69,"leadSponsor":71,"locationsCount":73},"100327317","pathophysiological-explorations-of-red-blood-cells-100327317","NCT03541525","Pathophysiological Explorations of Red Blood Cells","GR-Ex","Inclusion Criteria:\n\n* To be affected or have a family history of disease bound to the red blood cell,\n* For adult subjects, have signed an informed consent form,\n* For minor or major under legal safeguard subjects, the form must be signed by both parents (for minors) or by the legal representative,\n* Be affiliated to health insurance.\n\nExclusion Criteria:\n\n* Being deprived of freedom",true,{"count":60,"type":22},3750,"OBSERVATIONAL","GR-Ex is a program labelled by Labex (Laboratory of Excellence) by the French Ministry of Higher Education and Research. This program aims to develop the means to improve knowledge in the physiology and pathologies of erythropoiesis, red blood cells and iron metabolism, and to develop new therapeutic protocols capable of providing added value in terms of innovation.",[30],"2025-04-29",{"date":66,"type":42},"2025-04-30",{"date":68,"type":42},"2017-10-16",{"date":70,"type":22},"2037-10-15",{"name":72,"class":49},"Imagine Institute",25]